210 related articles for article (PubMed ID: 23482784)
1. Phase II study of carboplatin and weekly irinotecan combination chemotherapy in recurrent ovarian cancer: a Kansai clinical oncology group study (KCOG0330).
Tsubamoto H; Kawaguchi R; Ito K; Shiozaki T; Takeuchi S; Itani Y; Arakawa A; Tabata T; Toyoda S
Anticancer Res; 2013 Mar; 33(3):1073-9. PubMed ID: 23482784
[TBL] [Abstract][Full Text] [Related]
2. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
3. Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: a phase II trial.
Shawky H; Tawfik H; Hewidy M
J Egypt Natl Canc Inst; 2014 Sep; 26(3):139-45. PubMed ID: 25150129
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
6. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Strauss HG; Henze A; Teichmann A; Karbe I; Baumgart A; Thomssen C; Koelbl H
Gynecol Oncol; 2007 Mar; 104(3):612-6. PubMed ID: 17069876
[TBL] [Abstract][Full Text] [Related]
12. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
[TBL] [Abstract][Full Text] [Related]
13. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer.
Kim KH; Jelovac D; Armstrong DK; Schwartz B; Weil SC; Schweizer C; Alvarez RD
Gynecol Oncol; 2016 Feb; 140(2):210-4. PubMed ID: 26644263
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K
Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805
[TBL] [Abstract][Full Text] [Related]
15. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
[TBL] [Abstract][Full Text] [Related]
16. The "Leuven" paclitaxel/carboplatin weekly regimen in patients with recurrent ovarian cancer, a retrospective study.
Cadron I; Abdulkadir L; Despierre E; Berteloot P; Neven P; Leunen K; Amant F; Vergote I
Gynecol Oncol; 2013 Jan; 128(1):34-37. PubMed ID: 23063762
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
Sorbe B; Graflund M; Horvath G; Swahn M; Boman K; Bangshöj R; Lood M; Malmström H
Int J Gynecol Cancer; 2012 Jan; 22(1):47-53. PubMed ID: 22193643
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Escobar PF; Markman M; Rose P; Zanotti K; Webster K; Belinson J
Gynecol Oncol; 2004 Jan; 92(1):192-6. PubMed ID: 14751157
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Alvarez Secord A; Berchuck A; Higgins RV; Nycum LR; Kohler MF; Puls LE; Holloway RW; Lewandowski GS; Valea FA; Havrilesky LJ
Cancer; 2012 Jul; 118(13):3283-93. PubMed ID: 22072307
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
Kimball KJ; Numnum TM; Kirby TO; Zamboni WC; Estes JM; Barnes MN; Matei DE; Koch KM; Alvarez RD
Gynecol Oncol; 2008 Oct; 111(1):95-101. PubMed ID: 18692224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
